Skip to content
Adam Torkildson – Lifestyle
Author:
AriBio Co., Ltd.
AriBio’s Oral AR1001 Meets Primary Efficacy Objective in Prespecified Monotherapy Population in Phase 3 POLARIS-AD Trial
November 16, 2026